COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab
Neurology and Therapy
Open Access Publication
Rights and Permissions
Cross, A.H., Delgado, S., Habek, M. et al. COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. Neurol Ther 11, 741–758 (2022). https://doi.org/10.1007/s40120-022-00341-z This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Cross, Anne H and et al., "COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab." Neurology and Therapy. 11, 2. 741 - 758. (2022).
Table S1 and Figures S1-S4
s40120-022-00346-8.pdf (243 kB)
Correction to Covid-19 Outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab